⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
WVE News
Wave Life Sciences Ltd. Ordinary Shares
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
globenewswire.com
WVE
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
globenewswire.com
WVE
Form 8-K
sec.gov
WVE
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
WVE
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
WVE
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
globenewswire.com
WVE
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
globenewswire.com
WVE
ALNY
DNLI
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
globenewswire.com
WVE
Exploring Investment Opportunities in the Expanding RNA Therapy Clinical Trials Market: A USD 4.28 Billion Valuation by 2031
globenewswire.com
MRNA
BNTX
WVE
Exploring Investment Opportunities in the Expanding RNA Therapy Clinical Trials Market: A USD 4.28 Billion Valuation by 2031
globenewswire.com
MRNA
BNTX
WVE